CN104364260B - 胰岛素制剂 - Google Patents

胰岛素制剂 Download PDF

Info

Publication number
CN104364260B
CN104364260B CN201380030897.6A CN201380030897A CN104364260B CN 104364260 B CN104364260 B CN 104364260B CN 201380030897 A CN201380030897 A CN 201380030897A CN 104364260 B CN104364260 B CN 104364260B
Authority
CN
China
Prior art keywords
insulin
glu
formulation
desb30
ethyoxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380030897.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104364260A (zh
Inventor
H.纳维
M.施莱恩
D.B.斯蒂斯加亚尔德
I.V.佩特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN104364260A publication Critical patent/CN104364260A/zh
Application granted granted Critical
Publication of CN104364260B publication Critical patent/CN104364260B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380030897.6A 2012-04-11 2013-04-05 胰岛素制剂 Expired - Fee Related CN104364260B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12163730.0 2012-04-11
EP12163730 2012-04-11
US201261624463P 2012-04-16 2012-04-16
US61/624463 2012-04-16
EP13157748 2013-03-05
EP13157748.8 2013-03-05
US201361778554P 2013-03-13 2013-03-13
US61/778554 2013-03-13
PCT/EP2013/057196 WO2013153000A2 (en) 2012-04-11 2013-04-05 Insulin formulations

Publications (2)

Publication Number Publication Date
CN104364260A CN104364260A (zh) 2015-02-18
CN104364260B true CN104364260B (zh) 2017-02-22

Family

ID=49328249

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030897.6A Expired - Fee Related CN104364260B (zh) 2012-04-11 2013-04-05 胰岛素制剂

Country Status (11)

Country Link
US (1) US9481721B2 (https=)
EP (1) EP2836508B1 (https=)
JP (1) JP6199956B2 (https=)
KR (1) KR20150002777A (https=)
CN (1) CN104364260B (https=)
AU (1) AU2013247047A1 (https=)
BR (1) BR112014025132A2 (https=)
CA (1) CA2870313A1 (https=)
ES (1) ES2594303T3 (https=)
MX (1) MX2014012096A (https=)
WO (1) WO2013153000A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
PE20210857A1 (es) * 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
JP2020534939A (ja) * 2017-09-27 2020-12-03 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 漏出検出機能付きの流体供給装置
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN118754967A (zh) 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
AU2022300061A1 (en) * 2021-06-25 2024-02-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
US20250340610A1 (en) * 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
CN116284433B (zh) * 2022-07-04 2023-09-12 北京惠之衡生物科技有限公司 一种胰岛素和glp-1的缀合物及其应用
CN118063589A (zh) * 2024-02-04 2024-05-24 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067969A2 (en) * 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
WO2009115469A1 (en) * 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CN101573133A (zh) * 2006-07-31 2009-11-04 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832685A (en) 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
GB894095A (en) 1960-02-08 1962-04-18 Tanaka Shoichi A therapeutic device for personal wear
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3719655A (en) 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS6030650B2 (ja) 1979-10-26 1985-07-17 日本油脂株式会社 座薬基剤組成物
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
HU186826B (en) 1982-06-18 1985-09-30 Richter Gedeon Vegyeszet Method and apparatus for analysing of solution samples with high series number
EP0112861B1 (de) 1982-07-02 1988-01-27 Jugo-Import-Export-Anstalt Innenschalung für rotationssymmetrische Bauten
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US5266310A (en) 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH03506023A (ja) 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
AU6417790A (en) 1989-09-22 1991-04-18 Tsi-Madison Research Institute Method and compositions for one-step cryopreservation of embryos
KR930001305B1 (ko) 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DK45590D0 (https=) 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
AU8091091A (en) 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
AU8546591A (en) 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
CA2114141A1 (en) 1991-07-26 1993-02-18 Panayiotis Pericleous Constantinides W/o microemulsions
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
NZ245170A (en) 1991-11-26 1994-07-26 Lilly Co Eli Insulin and proinsulin analogues with arg at b31, b32 and ao and pharmaceutical compositions
ES2099193T3 (es) 1991-12-18 1997-05-16 Hoechst Ag Procedimiento para la obtencion de soluciones con contenido en insulina.
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
EP0666752A4 (en) 1992-10-16 1996-09-11 Smithkline Beecham Corp THERAPEUTIC MICROEMULSIONS.
JPH08502490A (ja) 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 組成物
EP0684833A4 (en) 1993-02-17 1996-09-11 Smithkline Beecham Corp MICRO-EMULSIONS COMPRISING THERAPEUTIC PEPTIDES.
EP0684834A4 (en) 1993-02-17 1996-09-25 Smithkline Beecham Corp MICROEMULSIONS CONTAINING THERAPEUTIC PEPTIDES.
AU685784B2 (en) 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CZ289343B6 (cs) 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
SK285019B6 (sk) 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
RU2218349C2 (ru) 1997-10-24 2003-12-10 Ново Нордиск А/С Агрегаты производных инсулина человека
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
AU8029798A (en) 1998-06-12 2000-01-05 Deutsches Wollforschungsinstitut Insulin analogue
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
CA2341624C (en) 1998-08-25 2008-12-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
UA65636C2 (uk) 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
WO2000043034A2 (en) 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1409640A (zh) 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
CZ20033182A3 (cs) 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
UY27439A1 (es) 2001-09-07 2003-04-30 Nobex Corp Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
AU2002362039B2 (en) 2001-12-03 2007-07-26 Soligenix, Inc Stabilized reverse micelle compositions and uses thereof
AU2002314790A1 (en) 2001-12-05 2003-06-23 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
UA46669C2 (uk) 2001-12-29 2005-12-15 Товариство З Обмеженою Відповідальністю "Мако" Спосіб приготування готової лікарської форми інсуліну пролонгованої дії
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1165549C (zh) 2002-06-15 2004-09-08 江苏万邦生化医药股份有限公司 胰岛素的纯化方法
WO2004026794A2 (en) 2002-09-17 2004-04-01 Merck & Co., Inc. Removal of aldehyde impurity by reactive polystyrene resin
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
PL1633876T3 (pl) 2003-06-17 2009-01-30 Sembiosys Genetics Inc Sposoby wytwarzania insuliny w roślinach
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
DK1648933T3 (da) 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
AU2004264958B2 (en) 2003-08-13 2010-04-15 Biocon, Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
EP1734938B1 (en) 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
CA2567056A1 (en) 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2006020580A2 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP1802287A2 (en) 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
JP2008528549A (ja) 2005-01-27 2008-07-31 ノボ ノルディスク アクティーゼルスカブ 構造的に充分に定義された分岐ポリマーと接合されたインスリン誘導体
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
WO2006103657A2 (en) 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
WO2007006320A1 (en) 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Drinkable oral insulin liquid and capsules
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
JP2010525033A (ja) 2007-04-30 2010-07-22 ノボ・ノルデイスク・エー／エス 高濃縮のインスリン溶液及び組成物
CN101677944A (zh) 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
EP2217621B1 (en) * 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
EP2370059A1 (en) 2008-11-28 2011-10-05 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
JP2012511506A (ja) 2008-12-09 2012-05-24 ノヴォ・ノルディスク・アー／エス 新規インスリンアナログ
EP2477644A1 (en) 2009-09-16 2012-07-25 Novo Nordisk A/S Stable non-aqueous liquid pharmaceutical compositions comprising an insulin
ES2552401T3 (es) 2009-11-02 2015-11-27 Novo Nordisk A/S Solución farmacéutica de albúmina unida no covalentemente e insulina acilada
CA2786953A1 (en) 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
WO2012049307A2 (en) 2010-10-15 2012-04-19 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067969A2 (en) * 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
CN101573133A (zh) * 2006-07-31 2009-11-04 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
WO2009115469A1 (en) * 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular variants and derivatives of insulin for improved glycemic control in diabetes;Sonika Bhatnagar，et al.;《Progress in Biophysics and Molecular Biology》;20060731;第91卷(第3期);第199–228页 *

Also Published As

Publication number Publication date
JP6199956B2 (ja) 2017-09-20
KR20150002777A (ko) 2015-01-07
WO2013153000A2 (en) 2013-10-17
EP2836508B1 (en) 2016-06-29
JP2015514120A (ja) 2015-05-18
US9481721B2 (en) 2016-11-01
BR112014025132A2 (pt) 2017-07-11
EP2836508A2 (en) 2015-02-18
US20150126442A1 (en) 2015-05-07
CA2870313A1 (en) 2013-10-17
CN104364260A (zh) 2015-02-18
WO2013153000A3 (en) 2013-12-05
MX2014012096A (es) 2014-11-21
AU2013247047A1 (en) 2014-10-23
ES2594303T3 (es) 2016-12-19

Similar Documents

Publication Publication Date Title
CN104364260B (zh) 胰岛素制剂
CN104667264B (zh) 包含胰岛素、烟酰胺和氨基酸的制剂
US20100222251A1 (en) Mixture comprising an amylin peptide and a protracted insulin
CN103249427A (zh) 速效胰岛素联合长效胰岛素
CN103328006A (zh) 包含胰岛素、烟酰胺和氨基酸的制剂
TWI880227B (zh) 澱粉素類似物之液體調配物
Senstius et al. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps
CN110305206A (zh) 一类双靶点多肽化合物及其在制备治疗糖尿病和以其为特征的病症的药物中的应用
RU2838627C2 (ru) Жидкие композиции аналогов амилина
US12616737B2 (en) Liquid formulations of amylin analogues
CA3240994C (en) Liquid formulations of amylin analogues
HK40104625B (en) Liquid formulations of amylin analogues
HK40104625A (en) Liquid formulations of amylin analogues
WO2024112231A1 (ru) Композиция быстродействующего инсулина (варианты)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Denmark bagsvaerd

Applicant after: NOVO NORDISK A/S

Address before: Denmark bagsvaerd

Applicant before: NOVO NORDISK A/S

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVO NORDISK A/S (A/S) TO: NOVO NORDISK A/S

Free format text: CORRECT: ADDRESS; FROM:

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170222

CF01 Termination of patent right due to non-payment of annual fee